The DOI matches its Crossref record.
Comparison of Intermediate-Dose Methotrexate with Cranial Irradiation for the Post-Induction Treatment of Acute Lymphocytic Leukemia in Children
Abstract
We compared two regimens with respect to their ability to prolong disease-free survival in 506 children and adolescents with acute lymphocytic leukemia. All responders to induction therapy were randomized to treatment with 2400 rad of cranial irradiation plus intrathecal methotrexate or to treatment with intermediate-dose methotrexate plus intrathecal methotrexate, as prophylaxis for involvement of the central nervous system and other "sanctuary" areas. Patients were then treated with a standard maintenance regimen. Complete responders were stratified into either standard-risk or increased-risk groups on the basis of age and white-cell count at presentation. Among patients with standard risk, hematologic relapses occurred in 9 of 117 given methotrexate and 24 of 120 given irradiation (P less than 0.01). The rate of central-nervous-system relapse was higher in the methotrexate group (23 of 117) than in the irradiation group (8 of 120) (P = 0.01). Among patients with increased risk, radiation offered greater protection to the central nervous system than methotrexate (P = 0.03); there was no difference in the rate of hematologic relapse. In both risk strata the frequency of testicular relapse was significantly lower in the methotrexate group (1 patient) than the radiation group (10 patients) (P = 0.01). Methotrexate offered better protection against systemic relapse in standard-risk patients and better protection against testicular relapse overall, but it offered less protection against relapses in the central nervous system than cranial irradiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia
Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look, A. T., Bowman, W. P., George, S. L., & Pui, C.-H. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140803 · Cited by 392
A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.06.007 · Cited by 368
Receptor-Mediated Peptide Transport through the Blood-Brain Barrier*
PARDRIDGE, W. M. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-3-314 · Cited by 313
High-dose methotrexate: a critical reappraisal.
Ackland, S. P., & Schilsky, R. L. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.12.2017 · Cited by 254
Metadata
- Authors
- Freeman, A. I., Weinberg, V., Brecher, M. L., Jones, B., Glicksman, A. S., Sinks, L. F., Weil, M., Pleuss, H., Hananian, J., Burgert, E. O., Gilchrist, G. S., Necheles, T., Harris, M., Kung, F., Patterson, R. B., Maurer, H., Leventhal, B., Chevalier, L., Forman, E., & Holland, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1983-03-03
- Volume
- 308
- Issue
- 9
- Pages
- 477-484
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2053215802
- Cited by
- 179
- References
- 0
- FWCI
- 30.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Intermediate-Dose Methotrexate with Cranial Irradiation for the Post-Induction Treatment of Acute Lymphocytic Leukemia in Children. https://app.cochat.ai/papers/10.1056/nejm198303033080902
- The paper
- Freeman, A. I., Weinberg, V., Brecher, M. L., Jones, B., Glicksman, A. S., Sinks, L. F., Weil, M., Pleuss, H., Hananian, J., Burgert, E. O., Gilchrist, G. S., Necheles, T., Harris, M., Kung, F., Patterson, R. B., Maurer, H., Leventhal, B., Chevalier, L., Forman, E., & Holland, J. F. (1983). Comparison of Intermediate-Dose Methotrexate with Cranial Irradiation for the Post-Induction Treatment of Acute Lymphocytic Leukemia in Children. New England Journal of Medicine. https://doi.org/10.1056/nejm198303033080902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.